Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$2.88
+0.2%
$2.55
$1.58
$5.02
$456.33M0.461.09 million shs799,203 shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$8.73
+1.3%
$8.99
$5.04
$15.36
$438.40M1.06930,242 shs423,944 shs
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$3.13
+32.6%
$2.61
$1.12
$3.20
$147.14M0.55864,044 shs10.56 million shs
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
$16.78
+3.6%
$16.81
$11.56
$29.79
$421.75M2256,004 shs59,085 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
0.00%+8.08%+16.87%+44.47%-19.92%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
0.00%+4.05%+4.43%+38.79%-19.32%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
0.00%+33.19%+19.01%+111.49%+131.85%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
0.00%+1.42%-11.20%+30.75%+30.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
1.9659 of 5 stars
3.63.00.00.00.61.70.0
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
4.5312 of 5 stars
3.43.00.04.62.33.30.6
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
2.1311 of 5 stars
3.53.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
3.20
Buy$7.60164.35% Upside
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2.83
Moderate Buy$31.63262.26% Upside
Theratechnologies Inc. stock logo
THTX
Theratechnologies
3.00
BuyN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3.00
Buy$49.33194.09% Upside

Current Analyst Ratings Breakdown

Latest THTX, TRML, MREO, and RGNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Theratechnologies Inc. stock logo
THTX
Theratechnologies
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/9/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$52.00
5/13/2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
4/23/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$70.00
4/17/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00
4/11/2025
Theratechnologies Inc. stock logo
THTX
Theratechnologies
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/9/2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$10M45.71N/AN/A$0.39 per share7.37
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$156.72M2.79N/AN/A$5.24 per share1.67
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$88.67M1.62N/AN/A($0.55) per share-5.69
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/A$11.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-$43.25M-$0.07N/AN/AN/AN/A-69.33%-57.27%8/12/2025 (Estimated)
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)
Theratechnologies Inc. stock logo
THTX
Theratechnologies
-$8.31M-$0.08N/A44.71N/A-4.18%N/A-0.37%7/9/2025 (Estimated)
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)

Latest THTX, TRML, MREO, and RGNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A
5/12/2025Q1 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$0.41$0.12-$0.29$0.12$105.35 million$89.01 million
5/2/2025Q1 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.91-$0.89+$0.02-$0.89N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
N/AN/AN/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/AN/AN/AN/AN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
N/A
8.92
8.92
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/A
2.93
2.93
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
1.08
0.88
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/A
33.87
33.87

Institutional Ownership

CompanyInstitutional Ownership
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
62.83%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
88.08%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
91.89%

Insider Ownership

CompanyInsider Ownership
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
5.50%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
12.79%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
13.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
40159.00 million150.26 millionOptionable
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
37050.16 million43.75 millionOptionable
Theratechnologies Inc. stock logo
THTX
Theratechnologies
14045.98 millionN/AOptionable
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4425.68 million22.35 millionOptionable

Recent News About These Companies

Tourmaline Bio Inc News (TRML) - Investing.com
TRML - Tourmaline Bio Inc Dividends - Morningstar
TRML - Tourmaline Bio Inc Executives - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Mereo BioPharma Group stock logo

Mereo BioPharma Group NASDAQ:MREO

$2.88 +0.01 (+0.17%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$2.88 0.00 (0.00%)
As of 07/3/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

REGENXBIO stock logo

REGENXBIO NASDAQ:RGNX

$8.73 +0.11 (+1.28%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$8.74 +0.00 (+0.06%)
As of 07/3/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Theratechnologies stock logo

Theratechnologies NASDAQ:THTX

$3.13 +0.77 (+32.63%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$3.16 +0.02 (+0.80%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Tourmaline Bio stock logo

Tourmaline Bio NASDAQ:TRML

$16.77 +0.59 (+3.61%)
Closing price 07/3/2025 03:43 PM Eastern
Extended Trading
$16.82 +0.04 (+0.24%)
As of 07/3/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.